Neurogene price target lowered to $50 from $55 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Neurogene (NGNE) to $50 from $55 and keeps a Buy rating on the shares. The firm expects positive updated clinical data in the second half of 2025, with a clear path forward for NGN-401. The selected go-forward low dose of NGN-401 appears to be significantly safer versus high-dose NGN-401, the analyst tells investors in a research note. H.C. Wainwright cut the price target after updating its expense projections for Neurogene.